Assessing the reliability of serum macrophage migration inhibitory factor as a marker for diabetic nephropathy prediction in type 2 diabetes patients and the effect of ACE inhibitors on its level

Authors

  • Sumaya B. Abdulrahman Department of Clinical Pharmacy, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
  • Eman S. Saleh Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
  • Sabah M. Saeedi Ministry of Health and Environment, Wasit Health Directorate, Wasit, Iraq.

DOI:

https://doi.org/10.31351/vol32iss2pp83-90

Keywords:

T2DM, Diabetic nephropathy, MIF, ACE inhibitors

Abstract

Abstract
Diabetic nephropathy (DN) is a prevalent chronic microvascular diabetic complication. As inflammation plays a vital role in the development and progress of DN the macrophages migration inhibitory factor (MIF), a proinflammatory multifunctional cytokine approved to play a critical function in inflammatory responses in various pathologic situations like DN. This study aimed To assess serum levels of MIF in a sample of Iraqi diabetic patients with nephropathy supporting its validity as a marker for predicting nephropathy in T2DM patients. In addition, to evaluate the nephroprotective effect of angiotensin-converting enzyme (ACE) inhibitors in terms of their influence on MIF levels. This is a case-control study involving ninety subjects that have been divided into three groups: twenty apparently healthy control group and seventy patients with type 2 diabetes mellitus divided into two equal groups according to the presence of diabetic nephropathy that has been further divided into two groups according to the use of ACE inhibitors or not. Serum MIF, urea, creatinine, RBS, HbA1c, BMI, eGFR, and urinary albumin to creatinine ratio have been measured for each subject. Serum MIF’s highest levels were observed in the diabetic nephropathy patients (24.9 ng/ml) followed by the diabetics (14. 1 ng/ml) with the lowest level observed in the control group (4.8 ng/ml). There was a significant relation between MIF levels and ACE inhibitors (p-value <0.05) with reduced MIF levels in ACE inhibitors users. The ROC curve showed that MIF has a good performance in disease prediction. These findings support the reliability of MIF as a biomarker for the prediction of diabetic nephropathy and the possible reducing effect of ACE inhibitors on MIF levels.

How to Cite

1.
Sumaya B. Abdulrahman, Eman S. Saleh, Sabah M. Saeedi. Assessing the reliability of serum macrophage migration inhibitory factor as a marker for diabetic nephropathy prediction in type 2 diabetes patients and the effect of ACE inhibitors on its level. Iraqi Journal of Pharmaceutical Sciences [Internet]. 2023 Sep. 27 [cited 2024 Dec. 22];32(2):83-90. Available from: https://bijps.uobaghdad.edu.iq/index.php/bijps/article/view/1993

Publication Dates

References

Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, Guerrero-Hue M, García-Caballero C, Vázquez-Carballo C, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020;21(11):1–43.

Kang I, Bucala R. The immunobiology of MIF: function, genetics and prospects for precision medicine. Nat Rev Rheumatol [Internet]. 2019;15(7):427–37. Available from: http://dx.doi.org/10.1038/s41584-019-0238-2

Klasen C, Ohl K, Sternkopf M, Shachar I, Schmitz C, Heussen N, et al. MIF Promotes B Cell Chemotaxis through the Receptors CXCR4 and CD74 and ZAP-70 Signaling. J Immunol. 2014;192(11):5273–84.

Bruchfeld A, Wendt M, Miller EJ. Macrophage migration inhibitory factor in clinical kidney disease. Front Immunol. 2016;7(JAN):1–7.

Guarneri M, Scola L, Giarratana RM, Bova M, Carollo C, Vaccarino L, et al. Susceptibility to End-Stage Renal Disease ( ESRD ). 2022;13.

Ruggenenti P, Cravedi P, Remuzzi G. The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol [Internet]. 2010;6(6):319–30. Available from: http://dx.doi.org/10.1038/nrneph.2010.58

Nakhoul R, Nakhoul F, Nakhoul N. Diabetic Nephropathy from RAAS to Autophagy: The Era for New Players. J Clin Exp Nephrol. 2017;2(3):1–8.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37:2864-83.

American Diabetes Association. 9. Microvascular complications and foot care. Diabetes Care 2016;39 Suppl 1:S72- 80.

Care D, Suppl SS. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 2021;44(January):S15–33.

Osman WM, Jelinek HF, Tay GK, Khandoker AH, Khalaf K, Almahmeed W, et al. Clinical and genetic associations of renal function and diabetic kidney disease in the United Arab Emirates: A cross-sectional study. BMJ Open. 2018;8(12).

Coates PT, Devuyst O, Wong G, Okusa M, Oliver J, York N, et al. KDIGO 2021 CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF BLOOD PRESSURE IN CHRONIC KIDNEY DISEASE. Int Soc Nephrol. 2021;99(3 S):S1–S87.

Araújo AA de, Araújo L de S, Medeiros CACX de, Leitão RF de C, Brito GA de C, Costa DV da S, et al. Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model. J Oral Pathol Med. 2018;47(10):972–84.

Yuhuan Z, Qiang W, Li T, Qian J, Lu Y, Li Y, et al. Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response. J Natl Cancer Inst. 2016;108(11):1–11.

Uddin Ismail B, Ali SFA, Ayaz AA, editors. Microcontroller Based Automated Body Mass Index (BMI) Calculator with LCD Display. 2nd International Conference on Electrical, Electronics and Civil Engineering (ICEECE’2012) Singapore April; 2012:28-29.

Alan H. B. Wu. Immunochemical Techniques. In: Michael L. Bishop, Edward P. Fody LES, editor. Clinical Chemistry Principles, Techniques, and Correlations. 8th ed. Philadelphia: Wolters Kluwer; 2018. p. 437–80.

Oyaert M, Delanghe J. Progress in automated urinalysis. Ann Lab Med. 2018;39(1):15–22.

Dharmarajan TS, Yoo J. Estimated Glomerular Filtration Rate and Muscle Mass in Older Patients: Diagnostic Accuracy of Creatinine-Based Equations and Implications in Practice. J Am Med Dir Assoc. 2020;21(4):566–7. doi.org/10.1016/j.jamda.2020.01.098

Jabbar TL, Kasim AA. Association of retinol binding protein- 4 (RBP4) with glycemia, dyslipidemia, hypertension, and obesity in type 2 diabetic Iraqi patients. Iraqi J Pharm Sci. 2021;29(2):263–70.

Saleh BH, Ali SH, Allehibi KI. Serum aldosterone level in patients with diabetic nephropathy in relation to vascular calcification. Iraqi J Pharm Sci. 2019;28(1):53–63.

Sánchez-Zamora YI, Rodriguez-Sosa M. The role of MIF in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2014;24(4):158–64.

Bruchfeld A, Carrero JJ, Qureshi AR, Lindholm B, Barany P, Heimburger O, et al. Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation. Mol Med. 2009;15(3–4):70–5.

Downloads

Published

2023-09-27

Issue

Vol. 32 No. 2 (2023): Iraqi J Pharm Sci

Section

Article

License

Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.